Filter by:
Muscular Dystrophy
June 2026
The Lancet
Effects of sevasemten (EDG-5506) on safety, biomarkers, and functional measures in adults with Becker muscular dystrophy: results of a phase 1b, open-label study
Muscular Dystrophy
March 2026
2026 MDA Clinical and Scientific Conference
Long-Term Stabilization of Function in Becker: Sevasemten Prevented Functional Decline Up to 3.5 Years with MESA Open-Label Extension
Muscular Dystrophy
March 2026
Industry Forum at the 2026 MDA Clinical and Scientific Conference
Elevating Becker Outcomes: Unlocking New Insights, Mobilizing Communities, and Redefining Care
Muscular Dystrophy
March 2026
2026 MDA Clinical and Scientific Conference
Female carriers of BMD and DMD mutations show elevated muscle injury proteins, and muscle loss progression is predicted by plasma ART3 concentration
Muscular Dystrophy
March 2026
2026 MDA Clinical and Scientific Conference
Effects of sevasemten on LVEF and NT-proBNP in adults with Becker muscular dystrophy in
Muscular Dystrophy
March 2026
2026 MDA Clinical and Scientific Conference
Patient-Focused Drug Development: Understanding the Patient Experience and Meaningful Treatment Outcomes in Becker Muscular Dystrophy via Qualitative Interviews
Muscular Dystrophy
December 2025
European Medical Journal
Breakthroughs in Becker: Unveiling New Natural History Insights and a Novel Agent’s Clinical Progress
Muscular Dystrophy
October 2025
World Muscle Society 2025
LYNX Phase 2 Trial Results in DMD: Positive Effects of Sevasemten, an Investigational Agent, on Physical Function Defines Dose and Informs Design for Phase 3
Muscular Dystrophy
October 2025
World Muscle Society 2025
